9 results about "Bacterial antigen" patented technology

The object of the present invention is to provide an active ingredient for a systemically administered mRNA pharmaceutical that expresses an antibody specific to the V antigen protein or its homologous protein of Gram-negative bacteria, and a systemically administered mRNA pharmaceutical using the same. [Solution] mRNA containing an antibody coding region encoding a specific scFv antibody against the V antigen protein or its homologous protein of pathogenic Gram-negative bacteria is useful as an active ingredient in mRNA pharmaceuticals for systemic administration.

The present invention relates to a combination therapy against pathogenic bacteria in the gut, wherein a bacteriophage against the capsule of the pathogenic bacterium is combined with a vaccination against a bacterial antigen which is normally masked by the capsule.

The invention belongs to the technical field of veterinary biology, and discloses an escherichia coli NK2 strain and application thereof in preparation of a mycoplasma hyopneumoniae culture medium. According to the invention, an Escherichia coli NK2 is screened, and the preservation number of the Escherichia coli NK2 is CCTCC (China Center For Type Culture Collection) NO: M20252722. The mycoplasma hyopneumoniae high-efficiency culture medium is prepared by the applicant by taking fermentation supernate of an endotoxin-removed escherichia coli NK2 strain as an auxiliary culture medium, the growth speed of the mycoplasma hyopneumoniae can be increased by adding the auxiliary culture medium, the culture time of the mycoplasma hyopneumoniae can be shortened, and the yield of the mycoplasma hyopneumoniae can be increased. Therefore, generation of aged bacteria is reduced, the viable count during culture harvesting is remarkably increased, the thallus antigen content during culture harvesting is remarkably improved, and the method has the advantages of being convenient to use, easy to obtain, low in cost, high in economic benefit and the like.

This invention belongs to the field of catalytic materials technology, specifically relating to a porous carbon biocatalytic material loaded with rhodium-iron bimetallic active sites, its preparation method, and its applications. The porous carbon biocatalytic material comprises a spiky porous carbon substrate, and rhodium clusters and iron single atoms uniformly loaded on its surface, forming Rh-Fe bimetallic active sites with charge transfer effects. The porous carbon biocatalytic material of this invention exhibits peroxidase-like and NADH oxidase-like activities under acidic conditions, and glucose oxidase-like, catalase-like, and superoxide dismutase-like activities under neutral conditions. It can efficiently kill bacteria and adsorb bacterial antigens, preventing macrophages from excessively polarizing to a pro-inflammatory state, ultimately promoting tissue regeneration and achieving ultra-rapid healing of inflammatory diabetic ulcers, with good biocompatibility.

The invention relates to a new topical nasal pharmaceutical composition for the treatment and prophylaxis of Rhinosinusitis (RS), comprising a homogeneous aqueous suspension with a therapeutically effective amount of the following well-known active ingredients: Rifamycin, an antibiotic and anti-inflammatory agent for topical or local use; fluticasone propionate, an anti-inflammatory agent for local use; optionally, oxymetazoline hydrochloride, a decongestant; and bacterial antigens, local immunostimulants; 0.9% saline solution, a vehicle; and pharmaceutically acceptable excipients q.s., which are formulated for topical administration via nasal spray. The combination of these compounds produces synergy, resulting in a greater local antibiotic, anti-inflammatory, decongestant and immunomodulatory effect at the specific site of action. Its effectiveness in chronic rhinosinusitis is particularly notable in low doses. So is its good tolerance, absence of adverse effects, and ease of application. No rebound congestion has been reported with prolonged use.

The invention discloses a vaccine composition which comprises a bacterial antigen and at least one drug carrier, the drug carrier is a saponin-containing polymer microsphere which is formed by freezing and thawing a polymer microsphere with a cavity structure so as to form an opening or a pore on the surface of the polymer microsphere, the preparation method of the vaccine composition comprises the following steps: mixing the drug carrier with a solution containing bacterial antigens, preferably enabling the bacterial antigens to be loaded on the drug carrier in modes of infiltration and / or adsorption and the like, and then centrifuging to remove supernate so as to obtain the polymer microspheres loaded with the antigens.

The invention relates to the technical field of mycoplasma hyopneumoniae detection, and particularly discloses a mycoplasma hyopneumoniae antibody detection kit which comprises a magnetic particle coating antigen, an acridinium ester labeled antibody, a standard substance, a quality control substance, a pre-excitation solution, an excitation solution and a washing solution. According to the invention, the recombinant P97CR1 protein is adopted as a coating antigen, and a double-antibody sandwich method is combined, so that the detection specificity is greatly enhanced, and the cross reaction interference of genetic pathogens is effectively eliminated; the problem that the false positive rate of traditional whole-cell antigen detection is high is solved, meanwhile, the antigen coating efficiency is improved through polydopamine (PDA) modified magnetic particles, a pre-excitation liquid / excitation liquid system composed of fluoboric acid and sodium hydroxide is adopted, the detection sensitivity is greatly improved, and the defect that an existing method cannot meet early diagnosis is overcome.

Bacterial antigen presenting cells are provided. Fusion proteins comprising a peptide-MHC complex, linker, and an autotransporter can be expressed on the surface of gram-negative bacteria, which can selectively stimulate T-cells reactive to the peptide-MHC complex. The bacterial antigen presenting cells can be used, e.g., to stimulate T-cells in vitro or in vivo.